Genentech has filed an Investigational New Drug Application for a follow-up to its tissue plasminogen activator (tPA) thrombolytic drug Activase (alteplase). Clinical trials of the new agent, called TNK, are expected to begin in early 1995. Preliminary data suggest that TNK may dissolve blood clots even faster than tPA. The company says it has also advanced an oral glycoprotein IIb/IIIa antagonist into full development to prevent vacular events such as myocardial infarction and stroke.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze